Detalhe da pesquisa
1.
Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study.
J Antimicrob Chemother
; 77(7): 1996-2002, 2022 06 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35403189